Related Experiment Video

Updated: Mar 24, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.9K

Coinhibitory Pathways in Immunotherapy for Cancer

Susanne H Baumeister1,2,3,4, Gordon J Freeman1,4, Glenn Dranoff1,5

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215.

Annual Review of Immunology
|March 2, 2016
PubMed

Insights

Cancer immunotherapy harnesses the immune system to fight tumors by targeting immune checkpoints. Blocking pathways like PD-1 and CTLA-4 can lead to durable responses in some patients, offering new hope for cancer treatment.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Immunotherapy

Background:

  • The immune system can identify and eliminate early-stage cancer cells.
  • Tumors develop mechanisms to evade immune surveillance, creating an immunosuppressive tumor microenvironment.
  • Immunological checkpoints regulate immune responses, maintaining self-tolerance and preventing autoimmunity.

Purpose of the Study:

  • To review the immunoregulatory functions of T cell coinhibitory pathways.
  • To discuss the translation of these pathways into effective cancer immunotherapies.
  • To highlight the role of immune checkpoints in tumor immune evasion.

Main Methods:

  • Review of existing scientific literature on coinhibitory pathways and cancer immunotherapy.
  • Analysis of the mechanisms by which tumors exploit coinhibitory pathways.
  • Examination of clinical data regarding checkpoint blockade therapies.

Main Results:

  • T cell coinhibitory pathways are exploited by tumors to evade immune eradication.
  • Blockade of Programmed Cell Death protein 1 (PD-1) and Cytotoxic T-Lymphocyte-Associated protein 4 (CTLA-4) checkpoints shows efficacy in a subset of cancer patients.
  • Combination therapies targeting multiple checkpoints are improving response rates.

Conclusions:

  • Understanding coinhibitory pathways is crucial for developing effective cancer immunotherapies.
  • Checkpoint blockade therapies, particularly targeting PD-1 and CTLA-4, represent a significant advancement in cancer treatment.
  • Further research into combination strategies holds promise for enhancing therapeutic outcomes.
Keywords:
CTLA-4PD-1PD-L1cancer immunotherapytumor immunity

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K
Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics12:19

Monitoring the Cancer-Immunity Cycle and Exploring Tumor Microenvironment Dynamics

Published on: June 7, 2024

2.2K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.1K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
7.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.3K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

4.2K